C. NOVYI FOR THE TREATMENT OF SOLID TUMORS IN HUMANS

    公开(公告)号:EP3730146A1

    公开(公告)日:2020-10-28

    申请号:EP20167187.2

    申请日:2014-03-28

    IPC分类号: A61K35/66 A61P35/00

    摘要: The present invention provides, inter alia, methods for treating or ameliorating an effect of a solid tumor present in a human. These methods include administering intratumorally to the human a unit dose of C. novyi, preferably C. novyi NT, colony forming units (CFUs), which contains about 1 x 10 3 -1 x 10 7 CFUs suspended in a pharmaceutically acceptable carrier or solution. Methods for debulking a solid tumor present in a human, methods for ablating a solid tumor present in a human, a method for microscopically precise excision of tumor cells in a human, methods for treating or ameliorating an effect of a solid tumor that has metastasized to one or more sites in a human, unit doses of C. novyi, preferably C. novyi NT, CFUs, and kits for treating or ameliorating an effect of a solid tumor present in a human are also provided.

    CANCER TREATMENTS USING COMBINATIONS OF PI3K/AKT PATHWAY AND ERK INHIBITORS
    10.
    发明公开
    CANCER TREATMENTS USING COMBINATIONS OF PI3K/AKT PATHWAY AND ERK INHIBITORS 审中-公开
    KREBSBEHANDLUNGEN UNTER VERWENDUNG VON KOMBINATIONEN AUS PI3K / AKT-SIGNALWEG- UND ERK-HEMMERN

    公开(公告)号:EP3082957A1

    公开(公告)日:2016-10-26

    申请号:EP14871139.3

    申请日:2014-12-19

    IPC分类号: A61P35/00

    摘要: The present invention provides, inter alia, methods, kits, and compositions for treating or ameliorating the effects of a cancer in a subject in need thereof. This method includes administering to the subject an effective amount of (i) a first anti-cancer agent, which is BVD-523 or a pharmaceutically acceptable salt thereof and (ii) a second anti-cancer agent, which is an inhibitor of the PI3K/Akt pathway or a pharmaceutically acceptable salt thereof. Also provided are methods of treating or ameliorating the effects of a subject with cancer in which the subject has a somatic KRAS and a somatic PIK3CA mutation or in which the cancer is refractory to a therapy selected from RAF inhibitor therapy, MEK inhibitor therapy, and RAF and MEK inhibitor therapy.

    摘要翻译: 本发明尤其提供用于治疗或改善有需要的受试者中癌症的作用的方法,试剂盒和组合物。 该方法包括向受试者施用有效量的(i)第一抗癌剂,其为BVD-523或其药学上可接受的盐,和(ii)第二种抗癌剂,其为PI3K的抑制剂 / Akt途径或其药学上可接受的盐。 还提供了治疗或改善患有癌症的受试者具有体细胞KRAS和体细胞PIK3CA突变或其中癌症对于选自RAF抑制剂治疗,MEK抑制剂治疗和RAF的治疗难治的方法 和MEK抑制剂治疗。